Latest Bio-Gene Technology (ASX:BGT) News

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.

Bio-Gene Technology has raised approximately A$3.275 million through its second tranche placement and share purchase plan underwriting, issuing over 51 million new shares and 69 million options to investors.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Bio-Gene Technology has expanded its capital raise to $2.775 million through a share placement priced at 2.5 cents, attaching options exercisable at 3.5 cents pending shareholder approval.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

One stock nearly doubled, another jumped more than 40%, and a finance heavyweight stayed elevated after a merger shock. In resources, the winners were mostly tied to “what was bought” or “what was funded”, while the laggards were often the ones where early optimism quickly turned into selling.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Bio-Gene Technology reports promising progress on its US Department of Defense-funded insecticide projects, with early mosquito mortality evidence from its Flavocide wearable device and pending launch of its Qcide indoor spray program.